Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
This Month's Highlights
You have accessRestricted Access

This Month’s Highlights

JASN March 2006, 17 (3) 593-594; DOI: https://doi.org/10.1681/ASN.2006010072
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Basic Science Articles

Polycystin-1 Activates PI3 Kinase/AKT Signaling.

Expression of polycystin-1 in MDCK cells promotes tubulogenesis and confers resistance to apoptosis. Boca et al. examined the mechanism underlying these effects. They found that expression of wild-type polycystin-1, but not mutant polycystin-1, activates phosphatidylinositol 3-kinase (PI3-kinase) and stimulates the phosphorylation of Akt (protein kinase B) and its downstream target FKRH-1. Akt has previously been shown to stimulate tubulogenesis and inhibit apoptosis. Expression of a dominant-negative Akt mutant prevents the resistance to apoptosis conferred by polycystin-1. Treatment with PI3-kinase inhibitors blocks phosphorylation of Akt and inhibits tubulogenesis. Recent studies suggest that inhibition of calcium-dependent activation of PI3-kinase and Akt leads to activation of ERK kinases and increases cell proliferation. Taken together, these findings suggest that polycystin-1 may exert its cellular effects by promoting calcium entry and activating the PI3-kinase/Akt signaling pathway. In autosomal dominant polycystic kidney disease, loss of polycystin-1 results in inhibition of PI3-kinase/Akt, increased ERK, and increased proliferation and apoptosis. See Boca et al., pages 637–647.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

A Way to Protect the Kidney from Injury Induced by Lithotripsy.

It is well established that in lithotripsy shock waves of sufficient intensity to disrupt stones also induce significant renal injury and some loss of function. Several years ago, Willis et al. reported that application of a therapeutic dose of shock waves to one pole of the kidney seemed to protect the opposite pole from injury when it was treated with the same dose later. In this study, these observations are extended to show that this protective effect is reproducible, that protection can be conferred by lower doses of shock waves that do not induce injury, and that protective doses can be applied prophylactically to the same area later treated with higher therapeutic doses. The study does not define the mechanism of the protective effect, but it offers an excellent model in which to do that and suggests that lithotripsy can likely be made a much safer and less injurious procedure than it currently is. See Willis et al., pages 663–673.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Regulatory T Cells Limit Proteinuric Renal Injury in Mice.

The pathogenesis of adriamycin nephropathy, a murine model of chronic proteinuric renal disease, involves both chemical and immunologic mechanisms. Published studies have implicated T lymphocytes as contributing to the development of this disease. To assess whether regulatory T cells could prevent adriamycin nephropathy, Wang et al. transduced CD4+ T cells with Foxp3, a transcription factor that is considered the “master switch” for induction of a regulatory T cell phenotype. The authors demonstrated that Foxp3-transduced T cells, but not controls, indeed exhibited features of regulatory/suppressor T cells. Moreover, adoptive transfer of the ex vivo–transduced regulatory T cells limited the functional and histologic manifestations of adriamycin nephropathy. This novel effect of Foxp3-transduced regulatory T cells on the development of chronic renal disease has potentially important therapeutic implications. See Wang et al., pages 697–706.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

How Is the Glomerulus Vascularized?

Vascular endothelial growth factor (VEGF) is a secreted protein that stimulates angiogenesis. During normal kidney development, VEGF produced by developing podocytes is required for the migration of endothelial cells into the glomerulus. Eremina et al. now show that VEGF is also required for mesangial cell migration and survival. Mice expressing a hypomorphic allele of VEGF are born with normal glomeruli but undergo mesangiolysis within 10 to 12 d after birth. Mesangiolysis is preceded by the loss of glomerular endothelial cells. The complete absence of VEGF in podocytes prevents the migration of mesangial cells into developing glomeruli. Mesangial cells do not express VEGF receptors, but they do express receptors for PDGF, a growth factor produced by endothelial cells. These findings suggest that the vascularization of the developing glomerulus proceeds via a two-step process in which VEGF produced by podocytes stimulates endothelial cell migration, then PDGF produced by glomerular endothelial cells stimulates mesangial cell migration. See Eremina et al., pages 724–735.

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

Clinical Science Articles

VEGF Gene Polymorphisms Associated with ESRD.

Doi et al. examine polymorphisms of the vascular endothelial growth factor (VEGF) gene in 101 male subjects with ESRD and 189 healthy controls in this issue of JASN. They found that two single nucleotide polymorphisms in the 3′ untranslated region of the gene are linked to each other and are significantly associated with ESRD. Sequence variation in the 3′ untranslated region of a gene does not affect the protein sequence but can affect mRNA stability. The VEGF gene polymorphisms are associated with higher circulating VEGF levels, which appear to be due to increased mRNA stability. Interestingly, overexpression of VEGF in mice (though to a much greater degree than observed in this study) results in a glomerular lesion similar to collapsing glomerulonephritis. Although the findings need to be confirmed in a larger prospective study, this study is the first to suggest that sequence variation in VEGF may be associated with the risk of ESRD in males. See Doi et al., pages 823–830.

Figure5
  • Download figure
  • Open in new tab
  • Download powerpoint

Does Preeclampsia Increase the Risk for Later Kidney Disease?

Preeclampsia is associated with increased risk of adverse maternal outcomes, including hypertension, cardiovascular disease, and persistent microalbuminuria. The report by Vikse and colleagues in this issue of JASN suggests that the kidney may not be spared the long-term consequences of this disease. They linked >750,000 women in two national registries to identify women with and without preeclampsia who underwent a subsequent kidney biopsy. They report that both preeclamsia and having an infant with low birth weight were independent risk factors for subsequent kidney biopsy during the next five years. Although the possibility that both the preeclampsia and subsequent kidney biopsy were due to unrecognized kidney disease cannot be totally excluded, these results emphasize the need to carefully exclude subclinical kidney disease among women presenting with antepartum hypertension and proteinuria both at initial evaluation and during subsequent follow-up. See Vikse et al., pages 837–845.

Figure6
  • Download figure
  • Open in new tab
  • Download powerpoint

Toward Optimal Dosing of Mycophenolic Acid.

Mycophenolic acid (MPA) is an immunosuppressant commonly used to prevent renal transplant rejection. Large between- and within-patient variability in the pharmacokinetics of MPA has been described, but this variability remains largely unexplained. In a retrospective meta-analysis of 468 renal transplant patients from 6 clinical trials, van Hest and colleagues explored the relationship between various clinical factors and the pharmacokinetics of MPA. The study revealed that exposure to MPA independently increased with increasing renal function, albumin, and hemoglobin as well as decreasing prednisone and cyclosporine levels, but was not independently influenced by delayed graft function, recipient race, or diabetes. The findings have clinical relevance in that a significant change in renal function or serum albumin could be used as an indication for therapeutic monitoring of MPA levels, in an effort to maximize efficacy and limit toxicity. See van Hest et al., pages 871–880.

Figure7
  • Download figure
  • Open in new tab
  • Download powerpoint

Should All Transplant Recipients Receive ACE/ARB Therapy?

The beneficial effects of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in reducing proteinuria, slowing progression, and reducing the risk for associated cardiovascular disease is well established in chronic kidney disease patients at high risk for cardiovascular disease. Similar data are not available for transplant recipients who also have chronic kidney disease. This retrospective study of 2031 patients from Austria looked at the effect of ACEI/ARB therapy on graft and patient survival in recipients of renal allografts, adjusting for other risk factors. Heinze et al. report a 20% higher 10-yr patient and graft survival rate in patients treated with ACEI/ARB therapy compared with those who were not. Although the study is retrospective and several important variables are not completely excluded as contributing to the findings, the magnitude of the differences observed are impressive and supports the use of these agents in transplant recipients until the results of prospective trials are available. See Heinze et al., pages 889–899.

Figure8
  • Download figure
  • Open in new tab
  • Download powerpoint
  • © 2006 American Society of Nephrology
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 17 (3)
Journal of the American Society of Nephrology
Vol. 17, Issue 3
March 2006
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
This Month’s Highlights
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
This Month’s Highlights
JASN Mar 2006, 17 (3) 593-594; DOI: 10.1681/ASN.2006010072

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
This Month’s Highlights
JASN Mar 2006, 17 (3) 593-594; DOI: 10.1681/ASN.2006010072
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Basic Science Articles
    • Clinical Science Articles
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • This Month's Highlights
  • This Month's Highlights
  • This Month's Highlights
Show more This Month's Highlights

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Polycystin-1 Induces Resistance to Apoptosis through the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway
  • Prevention of Lithotripsy-Induced Renal Injury by Pretreating Kidneys with Low-Energy Shock Waves
  • Foxp3-Transduced Polyclonal Regulatory T Cells Protect against Chronic Renal Injury from Adriamycin
  • Vascular Endothelial Growth Factor A Signaling in the Podocyte-Endothelial Compartment Is Required for Mesangial Cell Migration and Survival
  • Functional Polymorphisms in the Vascular Endothelial Growth Factor Gene Are Associated with Development of End-Stage Renal Disease in Males
  • Adverse Perinatal Outcome and Later Kidney Biopsy in the Mother
  • Explaining Variability in Mycophenolic Acid Exposure to Optimize Mycophenolate Mofetil Dosing: A Population Pharmacokinetic Meta-Analysis of Mycophenolic Acid in Renal Transplant Recipients
  • Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Type 1 Receptor Antagonist Therapy Is Associated with Prolonged Patient and Graft Survival after Renal Transplantation
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire